Parsons James T. 4

What Happened
James T. Parsons, a director of DiaMedica Therapeutics Inc. (DMAC), was granted 51,189 shares as a derivative award on June 1, 2026. The filing reports the acquisition price as $0.00 (a compensatory grant), so the reported transaction value is $0. This is an award/compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-01 (Form 4 filed 2026-06-03).
• Transaction type/code: A — Grant, award or other acquisition (derivative).
• Shares granted: 51,189 shares at $0.00 per share (total recorded value $0).
• Shares owned after transaction: Not specified in the filing.
• Footnote: F1 — The award is scheduled to vest in four substantially equal quarterly installments.
• Filing timeliness: Filed within the typical Form 4 window (not marked late in the filing).

Context
This was a compensatory equity award (likely restricted stock/RSUs or similar) that vests over time; such awards are standard executive/director compensation and do not by themselves indicate buying or selling intent. Because the grant is a derivative award with scheduled vesting, any future sales or taxes tied to vesting/withholding could result in later Form 4 entries.